REGENXBIO Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2025, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows:
| Rule 10b5-1 Trading Plan · Aggregate # of | ||||||
|---|---|---|---|---|---|---|
| Provides for · Securities to be | ||||||
| Name | Title | Action | Date Adopted | Expiration Date | Purchase/Sale | Purchased/Sold (a) |
| Mitchell Chan | Chief Financial Officer | Adoption | 8/12/2025 | 8/11/2026 | Sale | 156,401 |
(a)
The aggregate number of shares in this column includes shares that may be forfeited or withheld to satisfy exercise price and/or tax withholding obligations at the time of vesting.
Other than as described above, during the three months ended September 30, 2025, none of ourdirectors or Section 16 reporting officers adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.